Skip to content
HowShorted

Ernexa Therapeutics Inc. short interest in 2023

In 2023, Ernexa Therapeutics Inc.'s disclosed short interest ran from 1.11% of shares outstanding on 13 Jan 2023 to 2.48% on 29 Dec 2023, a change of +1.37 percentage points. The year's high was 2.48% on 31 May 2023 and its low 0.75% on 15 Feb 2023, averaging 1.79% across 23 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 47.00 days on 13 Oct 2023. Full history: Ernexa Therapeutics Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Ernexa Therapeutics Inc. in 2023

2023 in figures

Start of year
1.11% (13 Jan 2023)
End of year
2.48% (29 Dec 2023)
Change
+1.37 pp
High
2.48% (31 May 2023)
Low
0.75% (15 Feb 2023)
Average
1.79%
Highest days to cover
47.00 (13 Oct 2023)
SEC filings marked
5

Every report in 2023

Ernexa Therapeutics Inc. short interest in 2023
SettlementShort interestDays to coverFilings since previous
13 Jan 20231.11%1.02
31 Jan 20230.91%2.10
15 Feb 20230.75%1.00
28 Feb 20231.05%2.22
15 Mar 20231.33%6.90
31 Mar 20231.22%15.5010-K filed, results (8-K)
14 Apr 20231.59%11.86
28 Apr 20231.84%17.04
15 May 20231.51%6.5510-Q filed
31 May 20232.48%1.43
15 Jun 20231.93%5.90
30 Jun 20232.05%10.75
14 Jul 20232.02%7.93
31 Jul 20231.99%5.42
15 Aug 20231.81%9.1710-Q filed
31 Aug 20231.99%12.95
15 Sep 20232.41%7.18
29 Sep 20232.02%17.64
13 Oct 20232.05%47.00
31 Oct 20232.19%8.01
15 Nov 20232.28%6.1410-Q filed
30 Nov 20232.12%4.19
29 Dec 20232.48%4.53

See also: Ernexa Therapeutics Inc.'s full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.